Announced

Completed

Charles River Laboratories completed the acquisition of HemaCare for $380m.

Synopsis

Charles River Laboratories, which provides clinical tests and drug development services, completed the acquisition of HemaCare, which provides customized delivery of biological blood products and services, for $380m. “HemaCare advances the development of life-saving cell therapies through the use of its high-quality cellular products that represent critical inputs to these therapeutics. The addition of HemaCare’s innovative cell therapy products and services to our integrated, early-stage solutions will create a unique, go-to partner for clients to work with Charles River across a comprehensive cell therapy portfolio from idea to novel therapeutic,” James C. Foster, Charles River Laboratories Chairman, President, and Chief Executive Officer.

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Sort

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US